Business Wire

Quectel Introduces KCM0A5S Wi-SUN Module for Smart City and Smart Utility Devices

10.6.2025 15:00:00 CEST | Business Wire | Press Release

Share

Quectel Wireless Solutions, a global IoT solutions provider, has launched the Quectel KCM0A5S, a high-performance Wi-SUN module designed for smart applications such as street lighting, precision agriculture, industrial IoT, smart meters and smart cities. Based on Silicon Labs EFR32FG25, a sub-GHz low power wireless System on Chip, and featuring an ARM Cortex-M33 processor with a frequency of up to 97.5MHz, the module includes built-in 256KB RAM and 2MB Flash memory, ensuring efficient performance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610908069/en/

Quectel introduces KCM0A5S Wi-SUN module for smart city and smart utility devices

The Quectel KCM0A5S supports the Wi-SUN Field Area Network (FAN) 1.1 protocol and operates across the 470–928 MHz frequency range. The module utilizes IPv6-based wireless mesh networking technology, intrinsic to the Wi-SUN communication standard, to deliver long-range transmission, stable network connectivity and reliable data transmission. Furthermore, the KCM0A5S offers flexible deployment capabilities, supporting both router and leaf node configurations in standalone SoC mode, as well as acting as a border router when paired with a Linux host in RCP (Radio Co-Processor) mode. This versatility makes it an ideal solution for a wide range of mesh networking applications in smart city, utility, and industrial IoT deployments. In addition, the KCM0A5S features strong anti-interference capabilities and delivers excellent signal penetration which is of specific value for use cases in hard-to-reach locations. With a minimum of ten years product lifecycle and cross-version compatibility, the solution ensures long-term interoperability within Wi-SUN FAN networks.

“We’re delighted to launch the Quectel KCM0A5S Wi-SUN module,” said Delbert Sun, Vice General Manager, Product Department, Quectel Wireless Solutions. “Wi-SUN is a versatile LPWA connectivity technology that is applicable globally to a wide range of use cases. Its security, scalability and robustness provide compelling advantages to developers and device designers and the KCM0A5S adds to this with its ultra-compact form factor, high speed bandwidth and low latency. We look forward to helping customers to build a smarter world with the KCM0A5S as they bring the latest Wi-SUN enabled devices to market.”

Flexibility for developers and designers is assured thanks to the KCM0A5S’s ultra-compact LCC form factor. Dimensions of 28.0mm x 22.0mm x 3.15mm enable the size and cost of end products to be optimized, allowing for maximized design options. The module is also ideal for industrial-grade use cases with an operating temperature range of -40 °C to +85 °C. The module is available in variants that support a peak transmit power of 30 dBm—currently permitted in select regions such as North America, Latin America and some APAC countries—and offers both OFDM and FSK modulation schemes, subject to regional regulatory allowances.

Wi-SUN has been gaining traction for connecting IoT devices as a low power wide area (LPWA) connectivity solution because of its blend of scalability, security, interoperability and performance. It offers high speed bandwidth at up to 2.4Mbps with OFDM modulation. The technology is easily expandable and can support thousands of nodes. Wi-SUN’s self-forming and self-healing mesh eliminates single point of failure networks and simplifies deployment.

The combination of wide coverage, long distance of several kilometers and the ability to serve urban scenarios, covered by multi-hop mode is seeing Wi-SUN adopted for smart metering and smart city applications. For example, a control management system for street lighting, utilities and parking has been deployed in London that utilizes 15,000 Wi-SUN devices and 12 Wi-SUN border routers to enable real-time remote management and provide a future-proof system that can scale up as the city transitions to new infrastructure.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,600 professionals sets the pace for innovation in cellular, GNSS, satellite and Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610908069/en/

Contacts

Media contact: media@quectel.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye